Astra Zeneca

1. We began by understanding AstraZeneca's specific needs in their medical affairs team, focusing on the specialized fields of pancreatic cancer, small cell lung cancer, and hematology. We also assessed their requirements for candidates willing to relocate to Maryland.
2. We identified and mapped out the critical roles within the medical affairs team, pinpointing the necessary expertise and experience required for these niche positions. This allowed us to create a clear blueprint for the recruitment process.
3. Leveraging our extensive network and performing a thorough competitor analysis, we targeted talent pools across the US. Our outreach strategy included both active and passive candidates with the required physician background.
4. To attract candidates to Maryland, we created cost of living comparison brochures, highlighting the benefits and affordability of the area. This helped potential candidates see the value and feasibility of relocating.

1. We conducted a meticulous screening process to ensure candidates had not been previously considered by AstraZeneca. Each candidate was evaluated based on their experience, skills, and alignment with AstraZeneca's strategic objectives.
2. We managed the entire recruitment process, from initial screenings to competency-based interviews. Our approach ensured AstraZeneca received only the most qualified candidates, saving them valuable time and resources.
3. Upon candidate selection, we facilitated a smooth onboarding process, including regulatory compliance checks and ensuring candidates had the right-to-work in Maryland. We provided ongoing support to both AstraZeneca and the new hires to ensure a seamless transition.
4. Post-onboarding, we continued to offer support, managing legal and regulatory requirements while serving as a point of contact for any queries. This ongoing assistance ensured the successful integration of new hires into AstraZeneca's medical affairs team.

Within 13 days, we submitted 15 qualified candidates, with 10 progressing through further rounds. This diligent process resulted in the successful placement of two highly qualified medical directors. Additionally, AstraZeneca opened four new positions across various indications and seniorities based on the quality of the candidates presented.

These strategic hires have strengthened AstraZeneca's medical affairs capabilities in pancreatic cancer, small cell lung cancer, and hematology. This enhancement supports their clinical development and maintains their leadership in these critical therapeutic areas, ultimately improving patient outcomes and their competitive edge.